华森制药涨2.09%，成交额2832.63万元，主力资金净流入48.16万元

Core Insights - Huason Pharmaceutical's stock price increased by 2.09% on November 24, reaching 16.13 CNY per share, with a market capitalization of 6.736 billion CNY [1] - The company has seen a year-to-date stock price increase of 24.89%, but has experienced declines of 4.27% over the last five trading days, 5.06% over the last 20 days, and 12.50% over the last 60 days [2] - As of September 30, 2025, Huason Pharmaceutical reported a revenue of 626 million CNY, a year-on-year growth of 1.90%, while net profit attributable to shareholders decreased by 2.84% to 72.46 million CNY [3] Financial Performance - The company has made cumulative cash distributions of 192 million CNY since its A-share listing, with 100 million CNY distributed in the last three years [4] - As of September 30, 2025, the number of shareholders increased to 33,100, with an average of 9,063 circulating shares per shareholder, a decrease of 0.83% from the previous period [3] Business Overview - Huason Pharmaceutical, established on November 4, 1996, operates in the pharmaceutical industry, focusing on drug research, production, and sales [2] - The company's revenue composition includes 34.24% from otolaryngology drugs, 23.16% from digestive system drugs, 18.37% from psychiatric and neurological drugs, 15.02% from pharmaceutical commerce, and 7.76% from other fields [2] - The company is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine and related concepts such as innovative drugs and generic drugs [2]